Pediatric Neurology
Volume 28, Issue 2 , Pages 130-133 , February 2003

Topiramate effectiveness in Prader-Willi syndrome

  • Sarah A Smathers, BA

      Affiliations

    • Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, USA
    • ,
  • Jacquelyn G Wilson, PharmD, BCPP

      Affiliations

    • Ortho-McNeil Pharmaceutical, Inc., Raritan, New Jersey, USA
    • ,
  • Michael A Nigro, DO, FACN

      Affiliations

    • Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, USA
    • Children’s Hospital of Michigan, Department of Neurology, Detroit, Michigan, USA
    • Wayne State University School of Medicine, Departments of Pediatrics and Neurology, Detroit, Michigan, USA.Presented in part at the American Academy of Neurology 2001 Annual Meeting.
    • Corresponding Author InformationCommunications should be addressed to: Dr. Nigro; Michigan Institute for Neurological Disorders; 28595 Orchard Lake Road; Suite 200; Farmington Hills, Michigan 48334, USA.

Received 18 December 2001 ,Accepted 24 July 2002.

References 

  1. Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptochismus und oligophrenic nach myatomieartigem zustand in neugeborenalte. Schweizerishe Medizinishe Wochenschrift. 1956;86:1260–1261
  2. Nicholls RD, Knoll JHM, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. Nature. 1989;342:281–285
  3. Dimitropoulos A, Feurer ID, Roof E, et al.  Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi Syndrome. Ment Retard Dev Disabil Res Rev. 2000;6:125–130
  4. Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl. 1997;423:50–54
  5. Lindgren AC, Barkeling B, Hägg A, Ritzen EM, Marcus C, Rossner S. Eating behavior in Prader-Willi syndrome, normal weight and obese control groups. J Pediatr. 2000;137(1):50–55
  6. Rosenfeld WE. Topiramate (A review of preclinical, pharmacokinetic, and clinical data). Clin Ther. 1997;19(6):1294–1307
  7. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry. 1999;156(6):968–969
  8. Knable MB. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry. 2001;15(8):322–323
  9. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother. 2000;34:1262–1264
  10. Shapiro NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate (A clinical case series). J Clin Psychiatry. 2000;61:368–372
  11. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8(9):656–663
  12. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16:961–966
  13. Inoue S. Clinical studies with Mazindol. Obes Res. 1995;3:549; S-552S.
  14. Ebert MH, Schmidt DE, Thompson T, et al.  Elevated plasma Gamma-Aminobutyric Acid (GABA) levels in individuals with either Prader-Willi syndrome or Angelman syndrome. J Neuropsychiatry Clin Neurosci. 1997;9:75–80
  15. Gabreels BA, Swaab DF, Seidah NG, et al.  Differential expression of the neuroendocrine polypeptide 7B2 in hypothalami of Prader-(Labhart)-Willi syndrome patients. Brain Res. 1994;657:281–293
  16. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of anti-epileptic drugs in patients with seizure disorders. Neurology. 1999;53:S53–S67

PII: S0887-8994(02)00490-3

doi: 10.1016/S0887-8994(02)00490-3

Pediatric Neurology
Volume 28, Issue 2 , Pages 130-133 , February 2003

Article Tools

* Image Usage & Resolution